Stockreport

Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

Design Therapeutics, Inc.  (DSGN) 
PDF Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and [Read more]